Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]

摘要

This special issue of Current Pharmaceutical Design is focussed on innovative therapeutical approaches for hematologicalnmalignancies based on molecular targeted therapies. Macor group [1] summarizes recent advances in human tumor xenograftnmodels for moving toward more clinically relevant models, which are essential for characterizing potential therapeutic targetsnin cancer therapy, including hematological malignancies. Calin group [2] describes the potential involvement of microRNAs innthe regulation of neoplastic hematopoiesis and provides background on the biogenesis and function of miRNAs, discussing thenpotential therapeutic applications of miRNA-based technology in hematological malignancies. Phipps’ group [3] shows the linknbetween the overexpression of a key modulator of inflammation, such as cyclooxygenase-2 (Cox-2), and the ability of somenhematological malignancies to avoid immune responses by producing factors that enhance angiogenesis and the metastastaticnpotential. Thus, Cox-2 selective inhibitors, which are already used in clinical practice, have promising therapeutic also for thentreatment of hematological malignancies.